23 May 2013
Keywords: bioogen, elan, suspend, sales, tysabri, biogen, idec
Article | 07 March 2005
Biogen Idec of the USA and Ireland-based and Elan Corp have announced the voluntary suspension in the marketing of Tysabri ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 March 2005
28 February 2005
7 March 2005
© 2013 thepharmaletter.com